Presentations by Program :: Entasis Therapeutics

Outer Membrane Permeability and Efflux Do Not Limit Antibacterial Activity of Sulbactam-Durlobactamin Acinetobacter baumannii

Nicole M. Carter, Samir H. Moussa, Sarah M. McLeod, Alita A. Miller and Ramkumar Iyer

The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR Pseudomonas aeruginosa

Thomas Durand-Reville, Mark Sylvester, Janelle Comita, Frank Wu, Xiaoyun Wu, Jing Zhang, Jan Romero, Satenig Guler, Camilo Velez-Vega, Adam Shapiro, Nicole Carter, April Chen, Ramkumar Iyer, Samir Moussa, Sarah McLeod, Alita Miller, John O’Donnell and Ruben Tommasi

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants

Sarah McLeod, Nicole Carter, Ramkumar Iyer, Samir Moussa and Alita Miller

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Rana K, Wunderink R, Tsuei B, Rahav G, Kovalchuk E, Koksal I, Maloney K and Srinivasan S (IDWeek 2020)

Sulbactam-Durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug Resistant (MDR) Mycobacterium abscessus (Mab)

Dousa KM, Kurz SG, Bethel CR, Taracilla M, Miller AA and Bonomo RA (IDWeek 2020)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

An Adventure in Antibacterial Drug Discovery - Competing Methyl Effects on Biochemical Potency and Cell Accumulation

Tommasi R (BAARN 2020)